These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 26521718)

  • 21. Neoadjuvant Gemcitabine-Cisplatin Plus Radical Cystectomy-Pelvic Lymph Node Dissection for Muscle-invasive Bladder Cancer: A 12-year Experience.
    Iyer G; Tully CM; Zabor EC; Bochner BH; Dalbagni G; Herr HW; Donat SM; Russo P; Ostrovnaya I; Regazzi AM; Milowsky MI; Rosenberg JE; Bajorin DF
    Clin Genitourin Cancer; 2020 Oct; 18(5):387-394. PubMed ID: 32273235
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Emmprin Expression Predicts Response and Survival following Cisplatin Containing Chemotherapy for Bladder Cancer: A Validation Study.
    Hemdan T; Malmström PU; Jahnson S; Segersten U
    J Urol; 2015 Dec; 194(6):1575-81. PubMed ID: 26119672
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Favourable outcomes of patients with clinical stage T3N0M0 bladder cancer treated with induction low-dose chemo-radiotherapy plus partial or radical cystectomy vs immediate radical cystectomy: a single-institutional retrospective comparative study.
    Koga F; Kihara K; Fujii Y; Yoshida S; Saito K; Masuda H; Kageyama Y; Kawakami S
    BJU Int; 2009 Jul; 104(2):189-94. PubMed ID: 19154452
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Multicenter evaluation of the prognostic value of pT0 stage after radical cystectomy due to urothelial carcinoma of the bladder.
    May M; Bastian PJ; Burger M; Bolenz C; Trojan L; Herrmann E; Wülfing C; Müller SC; Ellinger J; Buchner A; Stief CG; Tilki D; Otto W; Höfner T; Hohenfellner M; Haferkamp A; Roigas J; Zacharias M; Wieland WF; Fritsche HM
    BJU Int; 2011 Oct; 108(8 Pt 2):E278-83. PubMed ID: 21699644
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neoadjuvant chemotherapy in the treatment of muscle invasive bladder cancer with mixed histology.
    Lin J; Whalen M; Holder D; Hruby G; Decastro GJ; McKiernan J
    Can J Urol; 2013 Apr; 20(2):6690-5. PubMed ID: 23587508
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cancer specific outcomes in patients with pT0 disease following radical cystectomy.
    Palapattu GS; Shariat SF; Karakiewicz PI; Bastian PJ; Rogers CG; Amiel G; Lotan Y; Vazina A; Gupta A; Sagalowsky AI; Lerner SP; Schoenberg MP;
    J Urol; 2006 May; 175(5):1645-9; discussion 1649. PubMed ID: 16600721
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Downstaging and survival benefits of neoadjuvant radiotherapy before cystectomy for patients with invasive bladder carcinoma.
    Granfors T; Tomic R; Ljungberg B
    Scand J Urol Nephrol; 2009; 43(4):293-9. PubMed ID: 19363744
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Retrospective Analysis of the Effect on Survival of Time from Diagnosis to Neoadjuvant Chemotherapy to Cystectomy for Muscle Invasive Bladder Cancer.
    Park JC; Gandhi NM; Carducci MA; Eisenberger MA; Baras AS; Netto GJ; Liu JJ; Drake CG; Schoenberg MP; Bivalacqua TJ; Hahn NM
    J Urol; 2016 Apr; 195(4 Pt 1):880-5. PubMed ID: 26598426
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Overall survival in patients with residual disease after radical cystectomy and neoadjuvant chemotherapy.
    Faiena I; Salmasi A; Mendhiratta N; Lenis AT; Pooli A; Drakaki A; Gollapudi K; Blumberg J; Pantuck AJ; Chamie K
    World J Urol; 2018 Nov; 36(11):1825-1833. PubMed ID: 29752514
    [TBL] [Abstract][Full Text] [Related]  

  • 30. P0 stage at radical cystectomy for bladder cancer is associated with improved outcome independent of traditional clinical risk factors.
    Kassouf W; Spiess PE; Brown GA; Munsell MF; Grossman HB; Siefker-Radtke A; Dinney CP; Kamat AM
    Eur Urol; 2007 Sep; 52(3):769-74. PubMed ID: 17434254
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Predictors of Complete Pathologic Response (pT0) to Neoadjuvant Chemotherapy in Muscle-invasive Bladder Carcinoma.
    Pokuri VK; Syed JR; Yang Z; Field EP; Cyriac S; Pili R; Levine EG; Azabdaftari G; Trump DL; Guru K; George S
    Clin Genitourin Cancer; 2016 Feb; 14(1):e59-65. PubMed ID: 26508364
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Downstaging to non-invasive urothelial carcinoma is associated with improved outcome following radical cystectomy for patients with cT2 disease.
    Tollefson MK; Boorjian SA; Farmer SA; Frank I
    World J Urol; 2012 Dec; 30(6):795-9. PubMed ID: 22447397
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Incidence, Characteristics and Implications of Thromboembolic Events in Patients with Muscle Invasive Urothelial Carcinoma of the Bladder Undergoing Neoadjuvant Chemotherapy.
    Duivenvoorden WC; Daneshmand S; Canter D; Lotan Y; Black PC; Abdi H; van Rhijn BW; Fransen van de Putte EE; Zareba P; Koskinen I; Kassouf W; Traboulsi SL; Kukreja JE; Boström PJ; Shayegan B; Pinthus JH
    J Urol; 2016 Dec; 196(6):1627-1633. PubMed ID: 27312316
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A phase II trial of neoadjuvant erlotinib in patients with muscle-invasive bladder cancer undergoing radical cystectomy: clinical and pathological results.
    Pruthi RS; Nielsen M; Heathcote S; Wallen EM; Rathmell WK; Godley P; Whang Y; Fielding J; Schultz H; Grigson G; Smith A; Kim W
    BJU Int; 2010 Aug; 106(3):349-54. PubMed ID: 20089114
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pathological Downstaging and Survival Outcomes Associated with Neoadjuvant Chemotherapy for Variant Histology Muscle Invasive Bladder Cancer.
    Chakiryan NH; Jiang DD; Gillis KA; Green E; Hajiran A; Hugar L; Zemp L; Zhang J; Jain R; Chahoud J; Poch M; Manley BJ; Li R; Sexton W; Gilbert SM
    J Urol; 2021 Oct; 206(4):924-932. PubMed ID: 34032503
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The importance of clinical stage among patients with a complete pathologic response at radical cystectomy after neoadjuvant chemotherapy.
    Parker WP; Ho PL; Boorjian SA; Melquist JJ; Thapa P; Holzbeierlein JM; Frank I; Kamat AM; Lee EK
    World J Urol; 2016 Nov; 34(11):1561-1566. PubMed ID: 26943643
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pathology-based risk stratification of muscle-invasive bladder cancer patients undergoing cystectomy for persistent disease after induction chemoradiotherapy in bladder-sparing approaches.
    Koga F; Fujii Y; Masuda H; Numao N; Yokoyama M; Ishioka J; Saito K; Kawakami S; Kihara K
    BJU Int; 2012 Sep; 110(6 Pt B):E203-8. PubMed ID: 22289431
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Urothelial Bladder Carcinoma (PURE-01): An Open-Label, Single-Arm, Phase II Study.
    Necchi A; Anichini A; Raggi D; Briganti A; Massa S; Lucianò R; Colecchia M; Giannatempo P; Mortarini R; Bianchi M; Farè E; Monopoli F; Colombo R; Gallina A; Salonia A; Messina A; Ali SM; Madison R; Ross JS; Chung JH; Salvioni R; Mariani L; Montorsi F
    J Clin Oncol; 2018 Dec; 36(34):3353-3360. PubMed ID: 30343614
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Gender-specific differences in cancer-specific survival after radical cystectomy for patients with urothelial carcinoma of the urinary bladder in pathologic tumor stage T4a.
    May M; Bastian PJ; Brookman-May S; Fritsche HM; Tilki D; Otto W; Bolenz C; Gilfrich C; Trojan L; Herrmann E; Moritz R; Tiemann A; Müller SC; Ellinger J; Buchner A; Stief CG; Wieland WF; Höfner T; Hohenfellner M; Haferkamp A; Roigas J; Zacharias M; Nuhn P; Burger M
    Urol Oncol; 2013 Oct; 31(7):1141-7. PubMed ID: 22056404
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pathological response to neoadjuvant chemotherapy for muscle-invasive micropapillary bladder cancer.
    Meeks JJ; Taylor JM; Matsushita K; Herr HW; Donat SM; Bochner BH; Dalbagni G
    BJU Int; 2013 Jun; 111(8):E325-30. PubMed ID: 23384236
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.